Prime Medicine, Inc. Current Income Tax Expense (Benefit)
Prime Medicine, Inc. (PRME) reported Current Income Tax Expense (Benefit) of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2024-03-01
- Prime Medicine, Inc. current income tax expense (benefit) for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Prime Medicine, Inc. current income tax expense (benefit) for fiscal 2022 was $16.00K, a 88.41% decline from fiscal 2021.
- Prime Medicine, Inc. current income tax expense (benefit) for fiscal 2021 was $138.00K.
- Prime Medicine, Inc. current income tax expense (benefit) for fiscal 2020 was $0.00.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-01 |
| 2022-12-31 | $16.00K 10-K · filed 2024-03-01 |
| 2021-12-31 | $138.00K 10-K · filed 2023-03-09 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |